Volgen
Josée Zijlstra
Josée Zijlstra
Associate Professor of Hematology, VU University Medical Center, Amsterdam
Geverifieerd e-mailadres voor vumc.nl
Titel
Geciteerd door
Geciteerd door
Jaar
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
R Boellaard, R Delgado-Bolton, WJG Oyen, F Giammarile, K Tatsch, ...
European journal of nuclear medicine and molecular imaging 42, 328-354, 2015
28812015
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ...
Journal of clinical oncology 25 (5), 571-578, 2007
16762007
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
R Boellaard, MJ O’Doherty, WA Weber, FM Mottaghy, MN Lonsdale, ...
European journal of nuclear medicine and molecular imaging 37, 181-200, 2010
15902010
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
A Engert, H Haverkamp, C Kobe, J Markova, C Renner, A Ho, J Zijlstra, ...
The Lancet 379 (9828), 1791-1799, 2012
7592012
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
6352012
Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma
M Schaapveld, BMP Aleman, AM van Eggermond, CPM Janus, ADG Krol, ...
New England Journal of Medicine 373 (26), 2499-2511, 2015
6122015
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
R Boellaard, WJG Oyen, CJ Hoekstra, OS Hoekstra, EP Visser, ...
European journal of nuclear medicine and molecular imaging 35, 2320-2333, 2008
4552008
Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
ML De Bruin, J Sparidans, MB van't Veer, EM Noordijk, MWJ Louwman, ...
Journal of Clinical oncology 27 (26), 4239-4246, 2009
4322009
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
B Von Tresckow, A Plütschow, M Fuchs, B Klimm, J Markova, A Lohri, ...
Journal of clinical oncology 30 (9), 907-913, 2012
3872012
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin …
P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ...
The Lancet 390 (10114), 2790-2802, 2017
3762017
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced …
C Kobe, M Dietlein, J Franklin, J Markova, A Lohri, H Amthauer, ...
Blood, The Journal of the American Society of Hematology 112 (10), 3989-3994, 2008
2812008
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review
JM Zijlstra, G Lindauer-van der Werf, OS Hoekstra, L Hooft, PC Huijgens
Haematologica 91 (4), 522-529, 2006
2762006
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ...
The Lancet Haematology 7 (7), e511-e522, 2020
2752020
Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review
JC Regelink, MC Minnema, E Terpos, MH Kamphuis, PG Raijmakers, ...
British journal of haematology 162 (1), 50-61, 2013
2552013
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non …
K Behringer, H Goergen, F Hitz, JM Zijlstra, R Greil, J Markova, S Sasse, ...
The Lancet 385 (9976), 1418-1427, 2015
2212015
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
E Vellenga, WLJ van Putten, MB van't Veer, JM Zijlstra, WE Fibbe, ...
Blood, The Journal of the American Society of Hematology 111 (2), 537-543, 2008
2172008
Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German …
M Fuchs, H Goergen, C Kobe, G Kuhnert, A Lohri, R Greil, S Sasse, ...
Journal of clinical oncology 37 (31), 2835-2845, 2019
2032019
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
LR Perk, OJ Visser, M Stigter-van Walsum, MJWD Vosjan, GWM Visser, ...
European journal of nuclear medicine and molecular imaging 33, 1337-1345, 2006
1982006
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
JEC Bromberg, S Issa, K Bakunina, MC Minnema, T Seute, M Durian, ...
The Lancet Oncology 20 (2), 216-228, 2019
1952019
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients
MAJ van Eijndhoven, JM Zijlstra, NJ Groenewegen, EEE Drees, ...
JCI insight 1 (19), 2016
1662016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20